Dashboard
Manage Tickers

MRUSMerus N.V.

Nasdaq merus.nl


$ 43.17 $ -0.96 (-2.18 %)    

Monday, 20-May-2024 14:41:45 EDT
CLICK TO SEE RELEVANT LITIGATION UPDATES
Y-mAbs Therapeutics, Inc. | YMAB | Take Action!
QQQ $ 454.82 $ 2.34 (0.52 %)
DIA $ 398.57 $ -1.31 (-0.33 %)
SPY $ 530.33 $ 0.78 (0.15 %)
TLT $ 91.26 $ 0.19 (0.21 %)
GLD $ 225.46 $ 2.10 (0.94 %)
$ 43.91
$ 44.13
$ 0.00 x 0
$ 0.00 x 0
$ 42.98 - $ 44.22
$ 19.81 - $ 52.04
486,819
na
2.55B
$ 1.05
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

petosemtamab-receives-breakthrough-therapy-designation-from-fda
Petosemtamab Receives Breakthrough Therapy...
05/13/2024 12:23:41

Merus N.V. announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation (BTD) for pe...

fda-grants-merus-breakthrough-therapy-designation-for-petosemtamab-for-treatment-of-patients-with-recurrent-or-metastatic-head-and-neck-squamous-cell-carcinoma
FDA Grants Merus Breakthrough Therapy Desi...
05/13/2024 12:21:26

needham-reiterates-buy-on-merus-maintains-66-price-target
Needham Reiterates Buy on Merus, Maintains...
05/13/2024 10:42:51

Needham analyst Ami Fadia reiterates Merus (NASDAQ:MRUS) with a Buy and maintains $66 price target.

hc-wainwright--co-reiterates-buy-on-merus-maintains-65-price-target
HC Wainwright & Co. Reiterates Buy on Meru...
05/09/2024 11:28:51

HC Wainwright & Co. analyst Andrew Fein reiterates Merus (NASDAQ:MRUS) with a Buy and maintains $65 price target.

merus-q1-eps-059-beats-081-estimate-sales-789m-miss-974m-estimate
Merus Q1 EPS $(0.59) Beats $(0.81) Estimat...
05/08/2024 22:35:42

Merus (NASDAQ:MRUS) reported quarterly losses of $(0.59) per share which beat the analyst consensus estimate of $(0.81) by 27.1...

merus-announces-us-fda-acceptance-and-priority-review-of-bla-for-zeno-for-the-treatment-of-nrg1-nsclc-and-pdac
Merus Announces U.S. FDA Acceptance And Pr...
05/06/2024 20:28:37

Merus N.V. (NASDAQ:MRUS) (Merus, the Company, we, or our), a clinical-stage oncology company developing innovative, full-length...

needham-reiterates-buy-on-merus-maintains-66-price-target
Needham Reiterates Buy on Merus, Maintains...
04/11/2024 09:42:47

Needham analyst Ami Fadia reiterates Merus (NASDAQ:MRUS) with a Buy and maintains $66 price target.

merus-presents-preclinical-data-demonstrating-efficacy-of-zeno-in-cancer-models-with-high-nrg1-expression-at-the-aacr-annual-meeting-2024
Merus Presents Preclinical Data Demonstrat...
04/08/2024 16:03:11

Merus N.V. (NASDAQ:MRUS) ("Merus", "the Company", "we", or "our"), a clinical-stage oncology co...

truist-securities-initiates-coverage-on-merus-with-buy-rating-announces-price-target-of-69
Truist Securities Initiates Coverage On Me...
03/28/2024 15:34:22

Truist Securities analyst Asthika Goonewardene initiates coverage on Merus (NASDAQ:MRUS) with a Buy rating and announces Pri...

needham-maintains-buy-on-merus-raises-price-target-to-66
Needham Maintains Buy on Merus, Raises Pri...
03/07/2024 11:06:41

Needham analyst Ami Fadia maintains Merus (NASDAQ:MRUS) with a Buy and raises the price target from $65 to $66.

Core News & Articles
Gilead and Merus Announce Collaboration To...
03/06/2024 13:05:34

merus-announces-publication-of-abstract-for-presentation-at-aacr-annual-meeting-2024
Merus Announces Publication Of Abstract Fo...
03/05/2024 21:31:08

needham-maintains-buy-on-merus-raises-price-target-to-65
Needham Maintains Buy on Merus, Raises Pri...
03/04/2024 10:35:46

Needham analyst Ami Fadia maintains Merus (NASDAQ:MRUS) with a Buy and raises the price target from $42 to $65.

on-wednesday-february-28-2024-merus-reported-q4-adjusted-eps-109-misses-074-estimate-sales-894m-miss-1013m-estimate
On Wednesday February 28, 2024, Merus Repo...
02/29/2024 20:26:12

Merus (NASDAQ:MRUS) reported quarterly losses of $(1.09) per share which missed the analyst consensus estimate of $(0.74) by 47...

hc-wainwright--co-maintains-buy-on-merus-raises-price-target-to-65
HC Wainwright & Co. Maintains Buy on Merus...
02/29/2024 20:24:26

HC Wainwright & Co. analyst Andrew Fein maintains Merus (NASDAQ:MRUS) with a Buy and raises the price target from $48 to...

stifel-maintains-buy-on-merus-raises-price-target-to-65
Stifel Maintains Buy on Merus, Raises Pric...
02/29/2024 17:43:44

Stifel analyst Bradley Canino maintains Merus (NASDAQ:MRUS) with a Buy and raises the price target from $40 to $65.

bmo-capital-maintains-outperform-on-merus-raises-price-target-to-58
BMO Capital Maintains Outperform on Merus,...
02/29/2024 13:08:48

BMO Capital analyst Etzer Darout maintains Merus (NASDAQ:MRUS) with a Outperform and raises the price target from $49 to $58.

as-of-december-31-2023-merus-had-4117m-cash-cash-equivalents-and-marketable-securities
As Of December 31, 2023, Merus Had $411.7M...
02/28/2024 22:04:13

Cash Runway, existing cash, cash equivalents and marketable securities expected to fund Merus' operations into 2027As of De...

needham-reiterates-buy-on-merus-maintains-42-price-target
Needham Reiterates Buy on Merus, Maintains...
12/04/2023 11:42:42

Needham analyst Ami Fadia reiterates Merus (NASDAQ:MRUS) with a Buy and maintains $42 price target.

merus-presented-updated-clinical-data-on-mcla-129-for-cancer-treatment-at-esmo-asia-2023
Merus Presented Updated Clinical Data On M...
12/04/2023 06:56:11

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION